{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T13:12:56Z","timestamp":1783861976764,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s12185-017-2238-9","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T09:44:03Z","timestamp":1493113443000},"page":"385-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1\/2 study"],"prefix":"10.1007","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9016-1948","authenticated-orcid":false,"given":"Arinobu","family":"Tojo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiichi","family":"Kyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuzo","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Miyamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Tugnait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayana I.","family":"Narasimhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lustgarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Farin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Haluska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"key":"2238_CR1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12185-008-0230-0","volume":"89","author":"WY Au","year":"2009","unstructured":"Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009;89:14\u201323.","journal-title":"Int J Hematol"},{"key":"2238_CR2","unstructured":"Kantar Health. Treatment Architecture: Japan-Leukemia, Chronic Myelogenous. CancerMPact\u00ae Japan, V1.4; 2013 (October 2014)."},{"key":"2238_CR3","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114:1126 (abstract).","journal-title":"Blood"},{"key":"2238_CR4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, For the IRIS Investigators, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054\u201361 (erratum, Leukemia. 2010; 24:1102).","journal-title":"Leukemia"},{"key":"2238_CR5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","volume":"34","author":"X An","year":"2010","unstructured":"An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34:1255\u201368.","journal-title":"Leuk Res"},{"key":"2238_CR6","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Br\u00fcmmendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome\u2013positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567\u201376 (erratum, Blood. 2013; 122:524).","journal-title":"Blood"},{"key":"2238_CR7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401\u201312.","journal-title":"Cancer Cell"},{"key":"2238_CR8","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome\u2013positive leukemias. N Engl J Med. 2012;367:2075\u201388.","journal-title":"N Engl J Med"},{"key":"2238_CR9","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","volume":"10","author":"JM Gozgit","year":"2011","unstructured":"Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011;10:1028\u201335.","journal-title":"Mol Cancer Ther"},{"key":"2238_CR10","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/leu.2012.8","volume":"26","author":"E Lierman","year":"2012","unstructured":"Lierman E, Smits S, Cools J, Dewaele B, Debiec-Rychter M, Vandenberghe P. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia. 2012;26:1693\u20135.","journal-title":"Leukemia"},{"key":"2238_CR11","unstructured":"Iclusig\u00ae (ponatinib) tablets, for oral use [prescribing Information]. Cambridge, MA: ARIAD Pharmaceuticals, Inc.; 2016. http:\/\/www.iclusigrems.com\/packaged\/pdf\/PI.pdf . Accessed on 19 February 2016."},{"key":"2238_CR12","unstructured":"Iclusig [summary of product characteristics]. Leatherhead, UK: ARIAD Pharma Ltd.; 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002695\/WC500145646.pdf . Accessed on 8 February 2016."},{"key":"2238_CR13","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, For the PACE Investigators, et al. A phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias. N Engl J Med. 2013;369:1783\u201396.","journal-title":"N Engl J Med."},{"key":"2238_CR14","unstructured":"Otsuka Pharmaceutical Co. L. Iclusig\u00ae Tablets 15 mg [prescribing information]; 2016. http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/180078_4291048F1020_1_01.pdf . Accessed on 1 December 2016."},{"key":"2238_CR15","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome\u2013positive leukemias. N Engl J Med. 2006;354:2531\u201341.","journal-title":"N Engl J Med"},{"key":"2238_CR16","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. for the IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"2238_CR17","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"2238_CR18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00280-014-2511-z","volume":"74","author":"NI Narasimhan","year":"2014","unstructured":"Narasimhan NI, Dorer DJ, Davis J, Turner CD, Marbury TC, Sonnichsen D. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol. 2014;74:341\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2238_CR19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40261-014-0225-y","volume":"34","author":"NI Narasimhan","year":"2014","unstructured":"Narasimhan NI, Dorer DJ, Davis J, Turner CD, Sonnichsen D. Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Drug Investig. 2014;34:723\u20139.","journal-title":"Clin Drug Investig"},{"key":"2238_CR20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/jcph.109","volume":"53","author":"NI Narasimhan","year":"2013","unstructured":"Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D. Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharmacol. 2013;53:974\u201381.","journal-title":"J Clin Pharmacol"},{"key":"2238_CR21","doi-asserted-by":"crossref","unstructured":"Cortes JE, Pinilla Ibarz J, Le Coutre PD, Paquette R, Chuah C, Nicolini FE, et al. 4-year results of the ponatinib phase 2 PACE trial in heavily pretreated leukemia patients [abstract 7013]. Presented at: Annual Meeting of the American Society of Clinical Oncology; June 3-7. Chicago, IL; 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.7013"},{"key":"2238_CR22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12185-014-1722-8","volume":"101","author":"C Nakaseko","year":"2015","unstructured":"Nakaseko C, Takahashi N, Ishizawa K, Kobayashi Y, Ohashi K, Nakagawa Y, et al. A phase 1\/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. Int J Hematol. 2015;101:154\u201364.","journal-title":"Int J Hematol"},{"key":"2238_CR23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s12185-009-0260-2","volume":"89","author":"H Sakamaki","year":"2009","unstructured":"Sakamaki H, Ishizawa K, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, et al. Phase 1\/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol. 2009;89:332\u201341.","journal-title":"Int J Hematol"},{"key":"2238_CR24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s12185-009-0327-0","volume":"89","author":"A Tojo","year":"2009","unstructured":"Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, et al. A Phase I\/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph\u00a0+\u00a0CML or relapsed\/refractory Ph+ALL. Int J Hematol. 2009;89:679\u201388.","journal-title":"Int J Hematol"},{"key":"2238_CR25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","volume":"48","author":"DJ Dorer","year":"2016","unstructured":"Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84\u201391.","journal-title":"Leuk Res"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-017-2238-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2238-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2238-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T05:49:34Z","timestamp":1601963374000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-017-2238-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["2238"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2238-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,25]]}}}